[Date]

UnitedHealthcare
Attn: Appeals and Grievances
[Plan/Unit if known]
Re: First-Level Appeal and Request for Retroactive Authorization/Coverage
Member: [Patient Name], [DOB]
Subscriber/Member ID: [Member ID]
Claim/Reference No.: [Claim Number]
Date(s) of Service: [Date(s)]
Rendering Provider/Facility: [Provider Name/Facility]
CPT/HCPCS Code: 70553 (MRI brain and/or cervical spine without contrast followed by with contrast and further sequences)
Denial Reason/Category: Prior authorization required (prior_auth)

To Whom It May Concern:

I am submitting this formal appeal on behalf of [Patient Name] to request reversal of UnitedHealthcare’s denial for CPT 70553 based solely on “Prior authorization required.” The requested study is a contrast-enhanced brain MRI (with pre- and post-contrast sequences) that is the evidence-based standard of care for the evaluation of suspected intracranial pathology as outlined by national guidelines and supported by high-level peer‑reviewed literature. The denial appears to be procedural rather than based on medical necessity; therefore, we seek retroactive authorization and coverage based on the medical necessity established below and UnitedHealthcare’s own utilization review framework.

Summary of the request and context
- Service requested: CPT 70553 — MRI of the brain and/or cervical spine without contrast followed by with contrast and additional sequences, including advanced techniques (e.g., perfusion/spectroscopy/diffusion) when indicated.
- Clinical indication: As reflected in the denial letter’s clinical findings, the study was ordered to evaluate suspected intracranial disease of clinical significance. There is no prior treatment history noted, and the MRI is necessary to establish diagnosis and guide management.
- Denial: Administrative/prior authorization requirement, not a determination that the imaging is not medically necessary.

Why the denial should be overturned
1) UnitedHealthcare’s utilization review process permits coverage determinations aligned with evidence-based clinical criteria. Your published notice states that Clinical Coverage Review evaluates requested services under applicable benefit documents and mandates using evidence-based medical policy and standardized clinical criteria (Source: UnitedHealthcare Notice of utilization review and benefit determination procedures – https://www.uhc.com/legal/required-state-notices/connecticut/notice-of-utilization-review). The requested MRI with contrast is squarely supported by authoritative guidelines and high-level evidence, as detailed below. When an initial request is denied for an administrative reason, retroactive authorization is appropriate once medical necessity is established under these criteria.

2) Medical necessity is established by national clinical guidelines.
- National Comprehensive Cancer Network (Primary CNS Lymphoma): “An MRI of the brain or spinal cord usually requires a contrast agent… Contrast highlights areas… to make them easier to see.” MRI scans can reveal one or multiple tumors; contrast is integral to accurate visualization and diagnosis (Source: National Comprehensive Cancer Network, Primary CNS Lymphoma, patient guideline – https://www.nccn.org/patients/guidelines/content/PDF/pcnsl-patient.pdf).
- National Comprehensive Cancer Network (Nasopharyngeal Cancer): Recommends MRI with contrast as part of initial staging and treatment planning for skull base/adjacent intracranial involvement: “MRI with contrast of collarbone to skull base. CT of skull base and neck may also be done.” These recommendations reflect the necessity of contrast-enhanced MRI for precise delineation adjacent to critical neurovascular structures (Source: National Comprehensive Cancer Network, Nasopharyngeal Cancer, patient guideline – https://www.nccn.org/patients/guidelines/content/PDF/hn-nasopharynx-patient.pdf).
- National Comprehensive Cancer Network (Acute Myeloid Leukemia): “Brain MRI with contrast, if leukemic meningitis suspected.” This underscores that contrast-enhanced brain MRI is the standard imaging modality when CNS involvement is a concern, given its superior sensitivity (Source: National Comprehensive Cancer Network, Acute Myeloid Leukemia, patient guideline – https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf).

These NCCN recommendations demonstrate that MRI with contrast is not optional but is the standard-of-care for multiple oncologic and neuro-oncologic presentations relevant to the differential diagnosis in suspected intracranial disease. Deferring or substituting non‑contrast imaging risks missed or delayed diagnosis.

3) High-level peer-reviewed evidence confirms the clinical superiority and necessity of contrast-enhanced MRI sequences in brain tumor evaluation.
- Dynamic contrast-enhanced (DCE) perfusion MRI has been broadly utilized in the evaluation of brain tumors, aiding in discrimination between low-grade and high-grade gliomas and in distinguishing recurrence from treatment effects (Source: PubMed – Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis – https://pubmed.ncbi.nlm.nih.gov/31389669/).
- In suspected glioblastoma, the recommended minimum MRI examination includes both pre- and post-gadolinium T1-weighted imaging, with additional sequences (e.g., diffusion/perfusion) to improve diagnostic confidence and differentiation (Source: PubMed – Critical Imaging for the Identification and Diagnosis of Glioblastoma – https://pubmed.ncbi.nlm.nih.gov/33215340/).
- Contrast Clearance Analysis (a contrast-based approach) demonstrates high diagnostic accuracy in differentiating tumor progression from treatment-related changes, outperforming or matching conventional techniques in systematic review/meta-analysis, underscoring the centrality of contrast-enhanced methods in neuro-oncology evaluation (Source: PubMed – Contrast clearance analysis in neuro-oncology – https://pubmed.ncbi.nlm.nih.gov/40746952/).
- For brain metastases, treatment response assessment relies on contrast-enhanced T1-weighted MRI as foundational, with pooled accuracies for advanced techniques reported across studies, again highlighting contrast as standard practice (Source: PubMed – Diagnostic accuracy of MRI techniques for treatment response evaluation in patients with brain metastasis: A systematic review and meta-analysis – https://pubmed.ncbi.nlm.nih.gov/36377093/).

Collectively, these Level I systematic reviews/meta-analyses support that contrast-enhanced MRI sequences are integral to accurate diagnosis, staging, and management decisions in neuro-oncology and related intracranial conditions—precisely the role of CPT 70553.

4) Federal coverage policies establish a strong benchmark that CPT 70553 and associated contrast are covered when medically necessary.
- CMS Medicare Claims Processing Manual instructs payment for contrast material supplied under Q9952 when billed with CPT codes including 70553 (Source: Centers for Medicare & Medicaid Services – https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c13.pdf).
- CMS LCD companion guidance explicitly references payment for contrast agents when billed with 70553 (Source: Centers for Medicare & Medicaid Services – https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/28723_57/l28723_rad024_cbg_100110.pdf).
- CMS National Coverage Determination for MRI (220.2) affirms diagnostic MRI coverage; CMS directs code-level details to related Billing & Coding Articles, demonstrating national acceptance of brain MRI when indicated (Source: Centers for Medicare & Medicaid Services – https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=177&ncdver=3&).
- CMS Billing and Coding: MRI and CT Scans of the Head and Neck provides claims processing parameters, further confirming covered status for head/neck MRI procedures consistent with CPT 70553 when medically necessary (Source: Centers for Medicare & Medicaid Services – https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57215).

Although Medicare policies do not directly govern a commercial plan, they represent authoritative federal standards widely aligned with commercial coverage and reinforce that contrast-enhanced brain MRI is a covered, standard diagnostic service.

5) UnitedHealthcare policies allow exceptions and retroactive consideration when medically necessary and when alternatives are inadequate.
- UnitedHealthcare’s Appeals and Grievances Process discusses coverage exceptions where alternatives would not be as effective or would cause adverse effects. While the page focuses on medications, the principle applies to utilization restrictions more broadly: when non-contrast imaging is inadequate for safe and effective care, exception or retro-authorization is warranted (Source: UnitedHealthcare – https://www.uhc.com/communityplan/learn-about-medicare/appeals-grievances-process).
- UnitedHealthcare’s published updates to specialty medical injectable drug programs show the use of prior authorization frameworks and exceptions for injectable agents in certain contexts, illustrating plan flexibility and clinical exception pathways when medically necessary (Source: UnitedHealthcare – https://www.uhc.com/agents-brokers/employer-sponsored-plans/news-strategies/specialty-medical-injectable-drug-program-updates-june2024).

While these latter policies address other benefit categories, they demonstrate that UnitedHealthcare’s prior authorization processes are intended to be evidence-based and adaptable to clinical need—precisely the situation here.

Addressing the stated denial rationale
- The current denial is procedural (“prior authorization required”) rather than a contention that CPT 70553 is not medically necessary. The medical record and the clinical findings referenced in your denial support the standard-of-care need for a contrast-enhanced brain MRI to promptly and accurately evaluate potential intracranial disease. Pursuant to UnitedHealthcare’s utilization review standards, and consistent with NCCN guidelines and Level I evidence cited above, the requested service meets evidence-based criteria.
- Given the urgent diagnostic role of MRI with contrast in suspected neuro-oncologic and other intracranial conditions, delaying or substituting non-contrast imaging risks missed pathology, imprecise staging, and inappropriate care. Retroactive authorization is appropriate to correct an administrative barrier that conflicts with established standards.

Requested resolution
- Approve coverage for CPT 70553 retroactively for the date(s) of service above, or issue expedited prior authorization if the study is pending.
- Confirm that associated contrast supply and technical/professional components will be covered consistent with CMS-aligned processing when medically necessary.
- If additional documentation is required (e.g., denial letter clinical findings, ordering notes, or imaging requisition), please notify us immediately; we will submit promptly.

Evidence sources (as referenced above)
- National Comprehensive Cancer Network, Primary CNS Lymphoma (patient guideline): https://www.nccn.org/patients/guidelines/content/PDF/pcnsl-patient.pdf
- National Comprehensive Cancer Network, Nasopharyngeal Cancer (patient guideline): https://www.nccn.org/patients/guidelines/content/PDF/hn-nasopharynx-patient.pdf
- National Comprehensive Cancer Network, Acute Myeloid Leukemia (patient guideline): https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf
- PubMed/NCBI – Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/31389669/
- PubMed/NCBI – Critical Imaging for the Identification and Diagnosis of Glioblastoma: https://pubmed.ncbi.nlm.nih.gov/33215340/
- PubMed/NCBI – Contrast clearance analysis in neuro-oncology: https://pubmed.ncbi.nlm.nih.gov/40746952/
- PubMed/NCBI – Diagnostic accuracy of MRI techniques for treatment response evaluation in patients with brain metastasis: A systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/36377093/
- UnitedHealthcare Notice of utilization review and benefit determination procedures: https://www.uhc.com/legal/required-state-notices/connecticut/notice-of-utilization-review
- UnitedHealthcare Appeals and Grievances Process: https://www.uhc.com/communityplan/learn-about-medicare/appeals-grievances-process
- UnitedHealthcare Specialty medical injectable drug program updates: https://www.uhc.com/agents-brokers/employer-sponsored-plans/news-strategies/specialty-medical-injectable-drug-program-updates-june2024
- CMS Medicare Claims Processing Manual: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c13.pdf
- CMS LCD companion (billing and coding guidance referencing CPT 70553): https://downloads.cms.gov/medicare-coverage-database/lcd_attachments/28723_57/l28723_rad024_cbg_100110.pdf
- CMS NCD – Magnetic Resonance Imaging (220.2): https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=177&ncdver=3&
- CMS Billing and Coding: MRI and CT Scans of the Head and Neck: https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=57215

Notes regarding available policy detail
- Our review did not identify a UnitedHealthcare policy document specific to CPT 70553 beyond the general utilization review materials cited above, nor state-specific mandates applicable to this member’s plan in the provided materials. Nonetheless, the federal CMS coverage documents and the NCCN/peer‑reviewed evidence constitute strong, widely accepted standards that UnitedHealthcare’s evidence-based criteria routinely reflect.

Thank you for your prompt reconsideration and approval. Please contact me at [Phone] or [Email] for any additional information or if an expedited review can be arranged based on medical urgency.

Sincerely,

[Provider Name], [Credentials]
[Practice/Facility Name]
[Address]
[Phone] | [Fax] | [Email]